GlassScriptPhysician profile
Melanie Mccarty
NPI 1225519432
$14,978.71
in general payments reported to CMS, 2019-2025
19 companies · $3,763 in 2025
The $3,763 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $927 · 2023: $313 · 2024: $9,721 · 2025: $3,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,280 · Travel and Lodging: $4,607 · Food and Beverage: $1,878 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,280.00 |
| Travel and Lodging | $4,606.81 |
| Food and Beverage | $1,878.16 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,814.13 | 2021-2025 | Epclusa |
| Abbvie INC. | $661.10 | 2021-2025 | |
| Uswm, LLC | $524.88 | 2022 | |
| Lilly USA, LLC | $183.53 | 2021-2024 | Mounjaro |
| Alkermes, INC. | $179.19 | 2021-2025 | Lybalvi, Vivitrol, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $126.69 | 2022-2024 | Farxiga |
| Allergan, INC. | $88.99 | 2022 | |
| Novo Nordisk INC | $63.29 | 2024-2025 | Wegovy |
| Amgen INC. | $51.57 | 2021-2024 | Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $48.19 | 2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $43.19 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $41.28 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Pfizer INC. | $36.64 | 2023-2024 | |
| Axsome Therapeutics, INC. | $24.67 | 2025 | Auvelity |
| Owp Pharmaceuticals, INC. | $22.54 | 2025 | Subvenite |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $19.43 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $19.06 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $16.79 | 2022 | |
| Corcept Therapeutics | $13.55 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.